Business Overview - Ceribell is an AI-powered point-of-care EEG platform targeting serious neurological conditions in the acute care setting[10] - The company estimates a U S annual addressable market of over $2 billion[13,64] - The company's 3Q 2025 revenue was $22 6 million, representing 31% year-over-year growth[13] - Ceribell has 615 active accounts as of 3Q 2025, with an 88% gross margin[13] Technology and Clinical Application - Ceribell's EEG system aims to provide suspicion to diagnosis in minutes, enabling earlier and more accurate treatment[39] - The system includes a headband EEG, portal, and recorder, combining portable hardware with AI-powered algorithms[43,44] - The Clarity algorithm provides seizure burden information to facilitate EEG reading for neurologists and offers real-time feedback on medication response[48,50] - Clinical data suggests that Ceribell can change clinical decisions in 20-53% of patients and reduce hospital or ICU length of stay by 0 4 to ~4 fewer days[56] Growth Strategy - Ceribell is pursuing growth by increasing adoption in new accounts, driving utilization within existing accounts, and expanding into new indications and markets[66] - The company has unlocked pediatric and neonate opportunities, opening an incremental ~$400 million market and ~280 children's hospitals[73]